Revvity (RVTY) Earnings Expected to Grow: Should You Buy?
Revvity (RVTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Revvity (RVTY) Beat Estimates Again in Its Next Earnings Report?
Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
Revvity's diagnostics strength and fast-growing Signals Software support long-term growth, even as macro pressures and weak funding linger.
Revvity, Inc. (RVTY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Revvity, Inc. (RVTY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Revvity says it will exceed 2025 profit forecast range
Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
RVTY & Eli Lilly Partner to Expand Access to AI Drug Discovery Models
Revvity teams up with Eli Lilly to bring TuneLab AI models to Signals Xynthetica, aiming to unlock secure, federated drug discovery at scale.
Revvity Advances AI-Driven Scientific Discovery With Signals Xynthetica
RVTY unveils Signals Xynthetica, an AI-augmented design platform that links predictive models with real lab data to speed discovery.
Revvity, Inc. (RVTY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Revvity, Inc. (RVTY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Revvity (RVTY) Up 9.5% Since Last Earnings Report: Can It Continue?
Revvity (RVTY) reported earnings 30 days ago. What's next for the stock?
Revvity, Inc. (RVTY) Presents at Jefferies London Healthcare Conference 2025 Transcript
Revvity, Inc. ( RVTY ) Jefferies London Healthcare Conference 2025 November 18, 2025 9:00 AM EST Company Participants Maxwell Krakowiak - Senior VP & CFO Prahlad Singh - CEO, President & Director Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Presentation Tycho Peterson Jefferies LLC, Research Division Okay. Thank you.
RVTY Q3 Earnings Beat, Sales In Line, '25 EPS View Raised
Revvity beats on Q3 earnings and raises 2025 EPS view, as balanced segment performance offsets margin pressure.
Revvity (RVTY) Surpasses Q3 Earnings Estimates
Revvity (RVTY) came out with quarterly earnings of $1.18 per share, beating the Zacks Consensus Estimate of $1.14 per share. This compares to earnings of $1.28 per share a year ago.
